PRODUCT INFORMATION

X-396

Item No. 44938

CAS Registry No.: 1370651-20-9
Formal Name: 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]carbonyl]phenyl]-3-pyridazinecarboxamide
Synonym: Ensartinib
MF: $C_{26}H_{27}Cl_2FN_6O_3$
FW: 561.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

X-396 is supplied as a solid. A stock solution may be made by dissolving the X-396 in the solvent of choice, which should be purged with an inert gas. X-396 is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

X-396 is an inhibitor of anaplastic lymphoma kinase (ALK) and MET (IC_{50}s = <0.4 and 0.74 nM, respectively).[1] It selectively inhibits the growth of cancer cell lines harboring gain-of-function ALK-fusion proteins (IC_{50}s = 9-106 nM) over those with cell growth driven by other mutant kinases (IC_{50}s = 757->3,000 nM). X-396 (25 mg/kg) reduces tumor growth in a lung cancer mouse xenograft model using NCI H3122 cells, which express a gain-of-function EML4-ALK fusion protein.

Reference

1. Lovly, C.M., Heuckmann, J.M., de Stanchina, E., *et al.* Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. *Cancer Res.* **71(14)**, 4920-4931 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM